Edwards Lifesciences (EW) Revenue — Quarter Ended Jun 30, 2024
Revenue increased in the quarter, driven by growth across the business. The company reported higher sales compared to both the prior quarter and the same period last year.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Revenue increased in the quarter, driven by growth across the business. The company reported higher sales compared to both the prior quarter and the same period last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.4B
Revenue reported for this quarter.
Quarter-over-quarter
+3.0%
Change from the immediately preceding quarter.
Year-over-year
+4.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2023 | $1.2B | -8.2% |
| Dec 31, 2023 | $1.3B | +194.6% |
| Mar 31, 2024 | $1.3B | +8.9% |
| Jun 30, 2024 | $1.4B | +4.4% |
Revenue performance
The reported revenue reflects an upward trend, with sequential and year-over-year improvements. The result is consistent with the company's recent growth trajectory.
Quarterly comparison
Revenue for the quarter was higher than the immediately preceding quarter and also exceeded the level from the same quarter one year earlier.
What to watch
Future quarters should be monitored for sustained growth, as the company has posted sequential revenue increases over the past several quarters.